The EFSA Panel on Contaminants in the Food Chain (CONTAM) established a tolerable daily intake (TDI) for fumonisin B 1 (FB 1 ) of 1.0 lg/kg body weight (bw) per day based on increased incidence of megalocytic hepatocytes found in a chronic study with mice. The CONTAM Panel considered the limited data available on toxicity and mode of action and structural similarities of FB 2-6 and found it appropriate to include FB 2 , FB 3 and FB 4 in a group TDI with FB 1 . Modified forms of FBs are phase I and phase II metabolites formed in fungi, infested plants or farm animals. Modified forms also arise from food or feed processing, and include covalent adducts with matrix constituents. Non-covalently bound forms are not considered as modified forms. Modified forms of FBs identified are hydrolysed FB 1-4 (HFB 1-4 ), partially hydrolysed FB 1-2 (pHFB 1-2 ), N-(carboxymethyl)-FB 1-3 (NCM-FB 1-3 ), N-(1deoxy-D-fructos-1-yl)-FB 1 (NDF-FB 1 ), O-fatty acyl FB 1 , N-fatty acyl FB 1 and N-palmitoyl-HFB 1 . HFB 1 , pHFB 1 , NCM-FB 1 and NDF-FB 1 show a similar toxicological profile but are less potent than FB 1 . Although in vitro data shows that N-fatty acyl FBs are more toxic in vitro than FB 1 , no in vivo data were available for N-fatty acyl FBs and O-fatty acyl FBs. The CONTAM Panel concluded that it was not appropriate to include modified FBs in the group TDI for FB 1-4 . The uncertainty associated with the present assessment is high, but could be reduced provided more data are made available on occurrence, toxicokinetics and toxicity of FB 2-6 and modified forms of FB 1-4 . and Alexander J, 2018. Scientific opinion on the appropriateness to set a group health-based guidance value for fumonisins and their modified forms. EFSA Journal 2018;16(2):5172, 75 pp. https://doi.This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union. HBGV for fumonisins and their modified forms www.efsa.europa.eu/efsajournal 2 EFSA Journal 2018;16(2):5172 HBGV for fumonisins and their modified forms www.efsa.europa.eu/efsajournal 3 EFSA Journal 2018;16(2):5172Although FBs are poorly absorbed, unchanged FBs excreted into urine have been used as a biomarker of exposure in humans. In animal studies changes in sphinganine (Sa) and sphingosine (So) and the Sa/So ratio can be determined in urine following FB exposure. A dose related increase in the sphinganine 1-phosphate (Sa 1-P)/sphingosine 1-phosphate (So 1-P) ratio in blood spots which correlated with urinary FB 1 levels has been reported in human studies. This result is consistent with fumonisin inhibition of CerS in humans.Toxicity studies deal mainly with effects of FB 1 , but FB 2-4 are considered as having similar toxicological profiles and potencies. FB 1 is considered not to be acutely toxic. In repeated dose st...